A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
Running, not enrolling · Phase 1
Conditions studied: Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Renal Cell Carcinoma
In brief
This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of \[225Ac\]-FPI-2068, \[111In\]-FPI-2107, and FPI-2053 in metastatic and/or recurrent solid tumors (HNSCC, NSCLC, mCRC, PDAC, GC, RCC).
Key facts
- Study ID
- NCT06147037
- Run by
- AstraZeneca
- People needed
- 13
- Starts
- 2024-07-31
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2026-07-07
Who can join
Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Palo Alto, California, United States
- Research Site — Chicago, Illinois, United States
- Research Site — Omaha, Nebraska, United States
- Research Site — Cleveland, Ohio, United States
- Research Site — Houston, Texas, United States
- Research Site — Seattle, Washington, United States
- Research Site — Montreal, Quebec, Canada
- Research Site — Sherbrooke, Quebec, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.